Drug Pipeline News

DiaMedica Therapeutics' investigational therapy DM199 significantly reduced blood pressure and improved uterine blood flow in patients with preeclampsia, with a favorable safety profile.

A roundup of the most impactful FDA approvals in women’s health from January through June 2025, spanning diagnostics, therapeutics, and at-home care.

Oral sulopenem (ORLYNVAH; Iterum Therapeutics) was non-inferior to amoxicillin/clavulanate for treating uUTIs in women, per the phase 3 REASSURE trial.

As strains of antibiotic-resistant gonorrhea spread, zoliflodacin provides an alternative oral treatment with non-inferiority to other methods.

GSK and Spero Therapeutics announced that the phase 3 PIVOT-PO trial for tebipenem HBr, a potential first oral carbapenem for cUTIs in the United States, was stopped early because of positive efficacy results.

A novel oral antibiotic, gepotidacin (Blujepa; GSK), has demonstrated its effectiveness in treating uncomplicated urogenital gonorrhea, according to the results of a recent phase 3 clinical trial.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

The approval marks a vital step toward care for urinary tract infections, helping to reduce recurrence and improve patients’ quality of life.

Ryan Haumschild, PharmD, MS, MBA, CPEL, explains the impact recently FDA-approved gepotidacin will have on uncomplicated UTIs and what this means in terms of antibiotic stewardship.

BlueWind Medical’s Revi System shows strong two-year efficacy and safety for UUI, with symptom reduction and high patient satisfaction.

Gameto’s Fertilo gets FDA clearance for a phase 3 trial, pioneering iPSC-based fertility treatment to shorten IVF cycles and improve reproductive care.

Vvax001, a new HPV16 vaccine, offers a potential alternative to surgery for treating precancerous cervical lesions, with promising trial results.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

The OASIS 4 clinical trial showed successful reductions in the frequency and severity of hot flashes caused by adjuvant endocrine therapy used in breast cancer management.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Study shows sildenafil cream 3.6% improves sexual arousal in diverse women with FSAD, offering hope for millions seeking effective treatment.

Rossella Nappi, MD, PhD, highlights how fezolinetant rapidly reduces the severity and frequency of hot flashes, offering a personalized, non-hormonal solution for menopausal women.

Iterum Therapeutics has announced the FDA has approved ORLYNVAH (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections (uUTIs)

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Ruth M Carrico, PhD, DNP, APRN, discusses the significance of the FLUBLOK vaccine's updated label, offering pregnant patients a safe and effective alternative for influenza prevention.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Sanofi’s influenza vaccine has received an updated label to include adult pregnant women following a trial indicating similar safety outcomes to standard influenza vaccination in this population.

Reunion Neuroscience is enrolling patients in its phase 2 RECONNECT trial to assess a single-dose synthetic psychedelic to treat the depressive symptoms of PPD.

In this 4-part interview, Kingsberg discusses the phase 2 RECONNECT trial assessing RE104 as the potentially first psychedelic to treat postpartum depression.

Elinzanetant, a non-hormonal drug, shows promising results in reducing hot flashes and night sweats, offering a new option for women seeking effective and safe treatment for vasomotor symptoms.